Our vision is to have screening covering all cancers, available to everyone, everywhere.
We are proud to say that in addition to the investors below, all senior managers are also investors in Tumour Trace.
Alexandar Obradovic is a successful Serbian entrepreneur who has been investing for several years in the research of the Opto-Magnetic Imaging Spectroscopy method and its application in characterising cancerous tissue. Alexandar made a further seed investment in Tumour Trace in 2015 to help start the process of creating a CE Marked device and to enable starting clinical trials.
Dr Johnson is an Angel investor in Tumour Trace. He is also a founder of Salix Pharmaceuticals, Inc. (NASDAQ: SLXP) in which he held senior positions prior to its recent $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX). Dr Johnson’s wealth of expertise gained while taking several therapeutic products through the full business life cycle is already proving invaluable to Tumour Trace as it prepares for clinical trials and selling into global markets.